Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment

NCT02523768 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Saint Etienne as lead sponsor.

NCT NCT02523768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02523768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Phase
Phase 4
Overall status
Terminated
Start date
January 8, 2011
Completion date
February 24, 2020
Enrollment
117 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

glomerulonephritis, igan